Carcinoembryonic Antigen (CEA) and Hepatic Metastasis in Colorectal Cancer: Update on Biomarker for Clinical and Biotechnological Approaches
| Autor: | José G. Dórea, Alexsandro Sobreira Galdino, Zulmira G. M. Lacava, Mariana Campos-da-Paz, Maria de Fátima Menezes Almeida Santos |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Colorectal cancer medicine.medical_treatment Cancer therapy Bioengineering Applied Microbiology and Biotechnology Metastasis Patents as Topic 03 medical and health sciences 0302 clinical medicine Carcinoembryonic antigen Internal medicine Biomarkers Tumor medicine Animals Humans neoplasms biology business.industry Liver Neoplasms medicine.disease Hepatic metastasis digestive system diseases Carcinoembryonic Antigen 030104 developmental biology 030220 oncology & carcinogenesis Radioimmunotherapy biology.protein Biomarker (medicine) Antibody Colorectal Neoplasms business Biotechnology |
| Zdroj: | Recent Patents on Biotechnology. 12:269-279 |
| ISSN: | 1872-2083 |
| DOI: | 10.2174/1872208312666180731104244 |
| Popis: | Background Carcinoembryonic Antigen (CEA) is a recommended prognostic marker in Colorectal Cancer (CRC) for tumor diagnosis and monitoring response to therapy. High CEA levels are specifically associated with CRC progression and increased levels of the marker are expected to fall following surgical treatment. Due to its role in CRC, CEA has also been explored as a target for cancer therapy and diagnosis approaches. Objective The goal of this work is to highlight the role of CEA in CRC progression and liver metastasis as well as its potential as a biomarker for clinical and biotechnological approaches. Method A literature search of electronic medical and patent databases Pubmed, Scopus, and Science Direct, Google patents, Esp@cenet and United States Patent and Trademark Office (USPTO), was performed. Information was collected in recent publications, including 81 articles besides 13 patents related to different CEA targeting biotechnological approaches for CRC therapy and diagnosis. Results CEA enhances CRC metastatic potential through many ways. CEA protects metastatic cells from death, changes the microenvironment of sinusoids, promoting the expression of adhesion molecule and malignant cell survival, besides being considered a proangiogenic molecule. Furthermore CEA has also been evaluated as a target in drug delivery systems, photodynamic therapy, radioimmunotherapy, cancer imaging and nanotechnological devices, leading to many patents concerning to development of anti-CEA antibodies or their fragments with potential to target colorectal cancer and liver metastasis cells. Conclusion CEA is already clinically used to monitor CRC patients, and it is a very promising targeting biomarker for multiple biotechnological applications. As far as we know this is the first report on CEA that addresses patents database. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|